CTRI/2018/03/012266招募中未知
Genzyme Rare disease registries (MPS I Disease Registry Protocol).
Sanofi Synthelabo India Private Limited0 个研究点目标入组 0 人开始时间: 待定最近更新:
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
入选标准
- •1. All age group from new born to old age allowed
- •2. All patients with a confirmed diagnosis of MPS I disease who are willing and able to provide written informed consent and any additional authorization documents required by local law to send health information to the Registry are eligible for inclusion, regardless of whether they are receiving disease therapy including ERT (such as laronidase) and irrespective of the commercial product with which they are being treated.
- •3. A confirmed diagnosis of MPS I consists of documented biochemical evidence of a deficiency in α-Liduronidase enzyme activity or mutation(s) in the gene coding for α-L-iduronidase
排除标准
- •No Exclusion Criteria
研究者
相似试验
尚未招募
不适用
Pompe Disease Registry.An observational program for patients with Pompe disease that was designed to track the natural history and outcomes of patients.CTRI/2018/03/012267Sanofi Synthelabo India Private Limited
招募中
不适用
Disease Registry for patients with Fabry disease.An observational program for patients with Fabry disease that was designed to track the natural history and outcomes of patients.CTRI/2018/03/012268Sanofi Synthelabo India Private Limited
招募中
不适用
Disease registry for patients with Gaucher disease.An observational program for patients with Gaucher disease that was designed to track the natural history and outcomes of patients.CTRI/2018/03/012357Sanofi Synthelabo India Private Limited
已完成
不适用
Central Information Portal for rare diseases - Sub-project 2: Information Request from patients and their families.Rare diseases.DRKS00006011niversität Hannover - Center for Health Economics Research92
尚未招募
不适用
development patient data set by recording and maintenance a registry at the national levelCTRI/2019/06/019661Indian Council of Medical Research